Indian firm Bharat Biotech has reported interim results from the Phase I clinical trial that showed its Covid-19 vaccine, COVAXIN (BBV152), induced a robust immune response with no serious adverse effects.

Developed in partnership with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), COVAXIN is a whole-virion, inactivated SARS-CoV-2 vaccine with two adjuvants – Algel (alum) and Algel-IMDG.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The vaccine, stored between 2°C and 8°C, is ideal for all national immunisation programme cold chain needs, Bharat Biotech noted.

Bharat Biotech is developing and manufacturing India’s indigenous Covid-19 vaccine at its Bio-Safety Level 3 (BSL-3) biocontainment facility.

The placebo-controlled, double-blinded clinical trial to evaluate the safety and immunogenicity of the vaccine enrolled approximately 375 participants.

Of these, 300 subjects received the vaccine doses while 75 subjects received the placebo.

Participants received two intramuscular doses of vaccine on day 0 (baseline) and day 14.

The trial’s primary outcomes were reactogenicity and safety, while secondary outcomes were immunogenicity based on the anti-IgG S1 response and wild-type virus neutralisation.

Interim data showed that on day 28, all participants who received the vaccine had significantly elevated Spike binding IgG antibodies and neutralising antibody titers.

The vaccine-induced antibody responses and could potentially neutralise both homologous (vaccine virus strain) and heterologous (divergent) SARS-CoV-2 strains.

Furthermore, researchers noted a Th1 biased T-cell response, with no serious (grade 3-4) adverse events reported.

Currently, the Phase II trials are in analysis.

In October, the Indian Central Drugs Standard Control Organisation (CDSCO) expert panel recommended granting approval to Bharat Biotech for conducting Phase III clinical trials of Covaxin.

In November, Bharat Biotech initiated Phase III trials of the vaccine, which will enrol 26,000 subjects across the country.